Shanghai Haoyuan Chemexpress Co., Ltd., established on September 30, 2006 and with 550 employees currently, is mainly engaged in R&D of related compounds in new drugs, R&D and sales of specialty pharmaceutical API, advanced intermediates, organic synthesis masonry and high-end reagents, technical development of chiral drugs, R&D of vitamin D derivatives, and development of active molecular libraries and new drug development reagents. At present, the company takes the lead globally in the fields of chemistry, biomedicine and other technologies. It also provides commissioned development of new drugs and generic drugs, drug certificate declaration and production technology improvement services for domestic and foreign pharmaceutical companies.
As a “specialized, refined, peculiar and new” small and medium-sized enterprise, Haoyuan Chemexpress possesses unique advantages in small molecular compounds. It has established a resource library containing more than 30,000 compounds; it owns more than 300 global exclusive compounds; it has mastered high-specific inhibitors and agonists acting on more than 300 target proteins in 20 signaling pathways; it has established 27 sub-compound libraries; it has a unique clinical phase compound library, closely following the R&D of pharmaceutical molecules to provide customers with the latest clinical small molecule compounds under research in a timely manner.
The company's featured products include: vitamin D series products; the new drug project “ADC Series Antibody Coupling Drugs R&D Project”; class I new drug “Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Coupling Agent for Injection” (RC48) obtains clinical approval, and it’s the first clinical ADC drug approved in China; a unique synthesis process and the reaction condition of triptolide are successfully developed; and complete synthesis of the natural product Trabectedin is finished.
Haoyuan Chemexpress has been awarded the following titles: National High-Tech Enterprise, Advanced Technology Service Enterprise, Brand Cultivation Demonstration Enterprise in Shanghai, Famous Service Enterprise in Shanghai, Patent Pilot Enterprise in Shanghai, R&D Institution in Pudong New Area, (Excellent) Little Giant Cultivation Enterprise, the Third Prize of Science and Technology in Pudong New Area, and MCE China Life Science Research Promotion Award. In terms of intellectual property rights, the company has been granted 19 patents, including 15 patents for inventions, 4 patents for utility models and 1 patent for appearance; 23 software copyright registration certificates; 47 domestic trademarks and 2 international trademarks.
At present, Haoyuan Chemexpress has established business centers and five warehouses in Shanghai, Hong Kong and the United States. Its sales network is distributed in 27 countries and regions, including France, Germany and Canada. It has established long-term and stable cooperation with thousands of well-known pharmaceutical companies, biotechnology companies, hospitals and research institutes around the world, including Novartis, AstraZeneca, Eli Lilly and Company, and The University of Hong Kong. In the future, Haoyuan Chemexpress, by continuing to adhere to the development philosophy of honesty, pragmatism and innovation, as well as core values of courage, responsibility, professionalism and efficiency, will be committed to becoming a world-class, industry-leading enterprise with customer satisfaction, social recognition and international competitiveness.